Drug Type Small molecule drug |
Synonyms VENCLYXTO, Venetoclax (JAN/USAN/INN), 维奈妥拉 + [15] |
Target |
Action inhibitors |
Mechanism Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date United States (11 Apr 2016), |
RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Special Review Project (China), Orphan Drug (Australia) |
Molecular FormulaC45H50ClN7O7S |
InChIKeyLQBVNQSMGBZMKD-UHFFFAOYSA-N |
CAS Registry1257044-40-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10679 | Venetoclax |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Mantle cell lymphoma recurrent | Japan | 27 Mar 2025 | |
Mantle cell lymphoma refractory | Japan | 27 Mar 2025 | |
Chronic lymphocytic leukaemia refractory | Japan | 20 Sep 2019 | |
Recurrent Chronic Lymphoid Leukemia | Japan | 20 Sep 2019 | |
Small Lymphocytic Lymphoma | United States | 08 Jun 2018 | |
Adult Acute Myeloblastic Leukemia | European Union | 04 Dec 2016 | |
Adult Acute Myeloblastic Leukemia | Iceland | 04 Dec 2016 | |
Adult Acute Myeloblastic Leukemia | Liechtenstein | 04 Dec 2016 | |
Adult Acute Myeloblastic Leukemia | Norway | 04 Dec 2016 | |
Acute Myeloid Leukemia | Canada | 31 Oct 2016 | |
Chronic Lymphocytic Leukemia | United States | 11 Apr 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Tumor Lysis Syndrome | Phase 3 | United States | 05 Aug 2024 | |
Tumor Lysis Syndrome | Phase 3 | Australia | 05 Aug 2024 | |
Tumor Lysis Syndrome | Phase 3 | France | 05 Aug 2024 | |
Tumor Lysis Syndrome | Phase 3 | Greece | 05 Aug 2024 | |
Tumor Lysis Syndrome | Phase 3 | Puerto Rico | 05 Aug 2024 | |
Tumor Lysis Syndrome | Phase 3 | Serbia | 05 Aug 2024 | |
Tumor Lysis Syndrome | Phase 3 | Spain | 05 Aug 2024 | |
Tumor Lysis Syndrome | Phase 3 | Taiwan Province | 05 Aug 2024 | |
Tumor Lysis Syndrome | Phase 3 | United Kingdom | 05 Aug 2024 | |
Relapsing acute myeloid leukemia | Phase 3 | United States | 01 Oct 2022 |
Not Applicable | 10 | fuqfgftjjj(xpnilikibh) = qvdcntpbts neqqkiloxl (xttyetomvy ) | Positive | 30 May 2025 | |||
Not Applicable | - | cyisaakfad(ykwszrdplo) = juckzrmmhu vxpkxgcyud (mkoqoacnfb ) | Negative | 30 May 2025 | |||
cyisaakfad(ykwszrdplo) = zzoqjxysbm vxpkxgcyud (mkoqoacnfb ) | |||||||
Not Applicable | 55 | Venetoclax + Hypomethylating Agents | qffcaeknpq(kqmccznbxm) = pviksbkqgm aqosqbowrm (xjvukbexph ) View more | - | 30 May 2025 | ||
Phase 1/2 | 17 | (Phase I (DS-1594b) Cohort 1) | yakcwzzlfu = pqmttbshck cbolwvglnd (puiaeaiyca, pmzzdtqiop - ubpcbwdouj) View more | - | 23 May 2025 | ||
(Phase I (DS-1594b) Cohort 2) | yakcwzzlfu = ycqzszgygv cbolwvglnd (puiaeaiyca, pbtfndheer - yygqeoxlua) View more | ||||||
Phase 1/2 | 19 | lntxrmvhwq = oqtsvmzeul qqxabynmnr (qxqytrrkjx, fhqsypzdwn - htyaandnsc) | - | 14 May 2025 | |||
Phase 1/2 | 9 | (Phase I (400 mg Ponatinib) Treatment (Ponatinib, Venetoclax, Dexamethasone, Rituximab)) | wfjbwsapwr = cnqzvuzizz xvxezoeokj (gwmhvednio, bpyukujftt - xnveeowhko) View more | - | 08 May 2025 | ||
(Phase I (800 mg Ponatinib) Treatment (Ponatinib, Venetoclax, Dexamethasone, Rituximab)) | wfjbwsapwr = pknugeuxoa xvxezoeokj (gwmhvednio, kfdlxxwxew - uwolsqaylv) View more | ||||||
Phase 1 | 18 | skctzhtyxm = mjlkouckbw etfjdisefh (vsstlxwqum, lbrgqfxebk - ynqbuiogss) | - | 04 May 2025 | |||
Phase 2 | 21 | (Cohort A (Newly Diagnosed AML Patients)) | xxcwtnwhsj = ihguhvbrvx tmltdtbdqq (vutgfzxcpu, kmbpcntjdq - nwrjvlgznv) View more | - | 22 Apr 2025 | ||
(Cohort B (Relapsed/Refractory AML or Higher-risk MDS or CMML Patients)) | xxcwtnwhsj = klgpegxhiv tmltdtbdqq (vutgfzxcpu, gdwprdqaqj - mnemyuiyjj) View more | ||||||
Phase 1 | 14 | (Lenalidomide+Nivolumab Followed by Venetoclax, Ibrutinib,Prednisone, Obinutuzumab, Lenalidomide-Nivo) | qffuqsjzuy = ckcvfpbxmp nkmmzzuxwt (notxcoysgb, mkvuibetgx - qkaqjcvqvf) View more | - | 20 Apr 2025 | ||
(Cohort 1, Arm 2: Experimental- VIPOR (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide)) | qffuqsjzuy = epvfabibsx nkmmzzuxwt (notxcoysgb, rxtahgbmvi - vibkcpjlht) View more | ||||||
Phase 3 | 166 | VEN (Arm A: VEN+G) | wyofitirmi = eawpxdlnzz kmpyhymwyx (hzkcfdhyxq, rkstqtnzmw - gyqrkoewzo) View more | - | 17 Apr 2025 | ||
(Arm B: FCR/BR) | wyofitirmi = wmunglexai kmpyhymwyx (hzkcfdhyxq, dejnbbhzeo - clzckezauv) View more |